Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

PJ Bingley; EAM Gale; Group European Nicotinamide Diabetes Intervebtion Trial (ENDIT)

doi:10.1007/s00125-006-0160-4

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

PJ Bingley, EAM Gale, Group European Nicotinamide Diabetes Intervebtion Trial (ENDIT)

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

102 Citations (Scopus)

Translated title of the contribution	Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk
Original language	English
Pages (from-to)	881 - 890
Number of pages	10
Journal	Diabetologia
Volume	49 (5)
DOIs	https://doi.org/10.1007/s00125-006-0160-4
Publication status	Published - May 2006

Bibliographical note

Publisher: Springer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-006-0160-4

http://tinyurl.com/39yp4v

Handle.net

Persistent link

Cite this

Bingley, PJ., Gale, EAM., & European Nicotinamide Diabetes Intervebtion Trial (ENDIT), G. (2006). Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia, 49 (5), 881 - 890. https://doi.org/10.1007/s00125-006-0160-4

@article{93db85c56f6845898bd14659ab85a141,

title = "Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk",

author = "PJ Bingley and EAM Gale and {European Nicotinamide Diabetes Intervebtion Trial (ENDIT)}, Group",

note = "Publisher: Springer",

year = "2006",

month = may,

doi = "10.1007/s00125-006-0160-4",

language = "English",

volume = "49 (5)",

pages = "881 -- 890",

journal = "Diabetologia",

issn = "1432-0428",

publisher = "Springer Berlin Heidelberg",

}

Bingley, PJ, Gale, EAM & European Nicotinamide Diabetes Intervebtion Trial (ENDIT), G 2006, 'Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk', Diabetologia, vol. 49 (5), pp. 881 - 890. https://doi.org/10.1007/s00125-006-0160-4

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. / Bingley, PJ; Gale, EAM; European Nicotinamide Diabetes Intervebtion Trial (ENDIT), Group.
In: Diabetologia, Vol. 49 (5), 05.2006, p. 881 - 890.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

AU - Bingley, PJ

AU - Gale, EAM

AU - European Nicotinamide Diabetes Intervebtion Trial (ENDIT), Group

N1 - Publisher: Springer

PY - 2006/5

Y1 - 2006/5

U2 - 10.1007/s00125-006-0160-4

DO - 10.1007/s00125-006-0160-4

M3 - Article (Academic Journal)

SN - 1432-0428

VL - 49 (5)

SP - 881

EP - 890

JO - Diabetologia

JF - Diabetologia

ER -